Vector Borne Diseases
8
0
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
38%
3 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Therapeutics for Moderate and Severe Dengue
Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum
Enhancing Protection Against Vector-borne Diseases in Forcibly Displaced Communities: Evaluating the Efficacy of Spatial Repellents for Cutaneous Leishmaniasis Control in North-East Syria
A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines
A Study to Compare Two Dosing Regimens for a New Malaria Vaccine
Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating
Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities
Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-endemic Participants in Cambodia